Amneal Pharmaceuticals (AMRX)
Developer and manufacturer of generics, injectables, biosimilars, and branded neurology medicines.
Something off on this page? Send us feedback.
Develops and manufactures retail generics, complex injectables, biosimilars, and branded neurology and endocrine medicines, while AvKARE distributes pharmaceutical and medical products to U.S. government, retail, and institutional customers. Operations span the United States, India, and Ireland, with prescriptions delivered primarily in the U.S.
Develops, manufactures, markets, and distributes medicines through Affordable Medicines, Specialty, and AvKARE. Affordable Medicines spans retail generics, complex injectables, and biosimilars; Specialty centers on branded neurology and endocrine treatments, including CREXONT, RYTARY, BREKIYA, and UNITHROID. AvKARE distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers.
Operations combine product development, manufacturing, and commercial distribution across the United States, India, and Ireland, with prescriptions delivered primarily in the United States. The portfolio emphasizes complex formulations and dosage forms that require specialized development and production capabilities. Market access depends on FDA product approvals and continuing compliance with current good manufacturing practices, while generic pricing typically declines as additional competitors enter. Revenue is concentrated among a limited number of products and customers.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Initiate | Rating: —Target: — | Target: $27 |
| Sep 17, 2026 | Barclays | Reiterate | Rating: —Target: $16 | Target: $20 |
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $23 |
| Aug 3, 2026 | UBS | Reiterate | Rating: —Target: $23 | Target: $25 |
| Jul 31, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $4 | Target: $21 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $127.6M · Total debt $2.79B · Total assets $3.78B · Shareholders' equity $33.0M
- Revenue
- $796.2M
- Operating income
- $146.0M
- Net income
- $57.7M
No dividends on record.
| Institutions | ≈ 51.40% | 164.15M shares | |
|---|---|---|---|
| 313 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 76.10% | 243.03M shares | |
| 19 holders · as of Sep 21, 2026 | |||
| Adds to | 127.50% | ||
319.35M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 127.50%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Tushar Bhikhubhai PatelInsider10 percent owner | 19.21% | 61.34M | filed Aug 12, 2026 |
Tushar PatelInsider | 19.21% | 61.34M | filed Aug 12, 2026 |
Chintu Patel1,2,3Insiderdirector, officer: Co-CEO | 10.20% | 32.58M | filed Aug 12, 2026 |
Chirag K. Patel4,5Insiderdirector, officer: President & Co-CEO | 9.11% | 29.10M | filed Aug 12, 2026 |
BlackRock, Inc.Institution | 8.32% | 26.56M | as of Jun 30, 2026 |
- Chintu Patel's transaction reports restate only vehicles that traded; the 2026 ownership statement (32.58M) is used instead.
- Chintu Patel reports a block also reported by Chirag K. Patel; it is counted once, under Chirag K. Patel.
- Chintu Patel reports a block also reported by another filer; it is counted once, under that filer.
- Chirag K. Patel's transaction reports restate only vehicles that traded; the 2026 ownership statement (29.10M) is used instead.
- Chirag K. Patel reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | John Kiely | director | −50,000 | $17.64 |
| Aug 12, 2026 | Jason B. Daly | officer: EVP, Chief Legal Officer | −210,000 | $17.40 |
| Aug 11, 2026 | Jason B. Daly | officer: EVP, Chief Legal Officer | −6,613 | $17.70 |
| Aug 12, 2026 | Nikita Shah | officer: Executive Vice President | −146,403 | $17.51 |
| May 11, 2026 | Deborah M. Autor | director | −34,819 | $12.94 |
- Teva (ADR)
World's largest generic-drug maker with US biosimilars and branded CNS franchise
- Viatris
US generics giant from Mylan+Pfizer Upjohn merger; 1,400+ molecules globally
- Dr. Reddy's Laboratories (ADR)
India-based global generics and biosimilars company with ~$1.7B US revenues
- Amphastar Pharmaceuticals
Injectable/inhalation generic specialist; direct peg-filgrastim biosimilar rival
- Supernus Pharmaceuticals
CNS specialty pharma with branded Parkinson's, ADHD, and epilepsy portfolio
- Jazz Pharmaceuticals
Specialty pharma leader in sleep and epilepsy; oxybate AG direct conflict
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals | $19.38 | −0.64% | $6.23B | 40.0 | 19.4 | 2.0 | +9.9% |
| Teva (ADR) | $39.60 | +0.19% | $46.03B | 65.9 | 14.1 | 2.7 | −0.8% |
| Viatris | $17.42 | +1.38% | $20.01B | — | 6.8 | 1.4 | +4.9% |
| Dr. Reddy's Laboratories (ADR) | $12.56 | −0.12% | $10.47B | 30.2 | 33.5 | 3.0 | −15.5% |
| Amphastar Pharmaceuticals | $24.48 | +0.66% | $1.07B | 14.4 | 7.7 | 1.5 | +5.4% |
| Supernus Pharmaceuticals | $44.06 | +0.70% | $2.54B | — | 15.2 | 3.1 | +32.4% |
| Jazz Pharmaceuticals | $239.86 | −0.30% | $15.11B | 16.4 | 9.5 | 3.3 | +15.6% |
| Median | 23.3 | 11.8 | 2.8 | +5.2% |